To sign up     Investment     Messages    HR


Your present location:首页 >> PRODUCTS >> VenusA-Valve® System >> VenusA-valve® System
  • 产品名称: VenusA-valve® System

As the aging population is growing in China, the numbers of patients who suffer valvular degeneration are increasing year by year. Study shows that about 2%-7% in elder people who age more than 65 are suffering from different levels of cardiac valvular degeneration, their clinical symptoms includes chest tightness, shortness of breath, chest pain (angina pectoris) and even sudden death. Some patients might lose their chance of proper treatment due to unsuitable for heart opening surgery. And there it is inefficient or a high death rate for medical treatment or simple balloon expansion treatment.
Proceeding transcatheter aortic valve implantation (TAVI or TAVR), a minimum invasive, low-risk treatment, brings the hope back for elder aortic stenosis patients, especially ones who are not suggested with open-heart surgery. TAVI has offered elder aortic stenosis patients a new choice.
The Venus A Transcatheter Artery Valve by Venus Medtech is a self-expand valve device. It has more reasonable design comparing to the similar devices in the U.S. and Europe. And it is easier to operate during surgery – more suitable for Chinese patients’ needs.
Venus A clinical research was conducted by academician Gao Run Lin, Fuwai Hospital Chinese Academy of Medical Science. So far, the first year of clinical trail has been completed, the death rate is 6.3% -- better performance comparing to similar products abroad. Venus A has completed national “125” technology supportive plan, and the country owns its intellectual property right and it is a aortic valve replacement which is more suitable for Chinese patients.
Regarded as a local out-standing brand, Venus A clinical live-demo surgeries has been conducted in CIT, CHC, Frankfurt CSI conference, Vietnam CSI-AP conference, PCR-CIT China Chengdu. The surgeries received good feedbacks, especially the Venus A live-demo on 13th Sep, 2014, Washington 26th TCT conference conducted by Fuwai Hospital Chinese Academy of Medical Science. That has brought the development of the Chinese valve industry to a new level.